title: CNA-loaded PLGA nanoparticles improve humoral response againstS. aureus-mediated infections in a mouse model: subcutaneous vs. nasal administration strategy.
abstract: The aim of this work was the assessment of the "in vivo" immune response of a poly(lactide-co-glycolide)-based nanoparticulate adjuvant for a sub-unit vaccine, namely, a purified recombinant collagen-binding bacterial adhesion fragment (CNA19), against Staphylococcus aureus-mediated infections. "In vivo" immunogenicity studies were performed on mice: immunisation protocols encompassed subcutaneous and intranasal administration of CNA19 formulated as nanoparticles (NPs) and furthermore, CNA19-loaded NPs formulated in a set-up thermosetting chitosan-β-glycerolphosphate (chitosan-β-GP) solution for intranasal route in order to extend antigen exposure to nasal mucosa. CNA19 loaded NPs (mean size of about 195 nm, 9.04 ± 0.37μg/mg as CNA19 loading capacity) confirmed as suitable vaccine for subcutaneous administration with a more pronounced adjuvant effect (about 3-fold higher) with respect to aluminium, recognised as "reference" adjuvant. CNA19 loaded NPs formulated in an optimised thermogelling chitosan-β-GP solution showed promising results for eliciting an effective humoral response and a good chance as intranasal boosting dose.
authors.affiliation: a Department of Drug Sciences , University of Pavia , Pavia , Italy.
authors.forename: Ida
authors.initials: I
authors.lastname: Genta
authors.affiliation: a Department of Drug Sciences , University of Pavia , Pavia , Italy.
authors.forename: Claudia
authors.initials: C
authors.lastname: Colonna
authors.affiliation: a Department of Drug Sciences , University of Pavia , Pavia , Italy.
authors.forename: Bice
authors.initials: B
authors.lastname: Conti
authors.affiliation: b Department of Pharmaceutical Sciences , University of Padua , Padova , Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Caliceti
authors.affiliation: b Department of Pharmaceutical Sciences , University of Padua , Padova , Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Salmaso
authors.affiliation: c Department of Molecular Medicine, Unit of Biochemistry , University of Pavia , Pavia , Italy.
authors.forename: Pietro
authors.initials: P
authors.lastname: Speziale
authors.affiliation: c Department of Molecular Medicine, Unit of Biochemistry , University of Pavia , Pavia , Italy.
authors.forename: Giampiero
authors.initials: G
authors.lastname: Pietrocola
authors.affiliation: a Department of Drug Sciences , University of Pavia , Pavia , Italy.
authors.forename: Enrica
authors.initials: E
authors.lastname: Chiesa
authors.affiliation: a Department of Drug Sciences , University of Pavia , Pavia , Italy.
authors.forename: Tiziana
authors.initials: T
authors.lastname: Modena
authors.affiliation: a Department of Drug Sciences , University of Pavia , Pavia , Italy.
authors.forename: Rossella
authors.initials: R
authors.lastname: Dorati
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D000281:Administration, Intranasal; D000818:Animals; D004337:Drug Carriers / Q000737:chemistry*; D005260:Female; D056724:Immunity, Humoral; D019344:Lactic Acid / Q000737:chemistry*; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000737:chemistry*; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D013203:Staphylococcal Infections / Q000276:immunology / Q000517:prevention & control*; D013209:Staphylococcal Vaccines / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D013211:Staphylococcus aureus / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000276:Adjuvants, Immunologic; D004337:Drug Carriers; D013209:Staphylococcal Vaccines; D014614:Vaccines, Synthetic; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid
keywords: PLGA nanoparticles; S. aureus-mediated infections; in vivo immunisation; nano-sized adjuvant; nasal vaccination; thermosetting polymeric solution